Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.
Lexaria signed an MTA with PegBio to test a GLP-1 drug using DehydraTECH oral delivery technology. The partnership validates DehydraTECH in the high-growth GLP-1 market, positioning Lexaria for licensing deals with major pharma players.
Lexaria Bioscience Corp.
(NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd.
Here's what investors need to know.
Lexaria Bioscience shares are climbing with conviction.
What's driving LEXX stock higher?
19:50 EDT Lexaria Bioscience (LEXX) Corp trading halted, news pendingClaim 55% Off TipRanks Unlock powerful investing tools with…
KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global…
Potentially Valuable Novel Compositions Being Investigated
KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global…
Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA…
